Aims: In radiotherapy trials, normal tissue effects (NTE) are important end points and it is pertinent to ask whether patient-reported outcome measures (PROMs) could replace clinical and/or photographic assessments. Data from the Standardisation of Breast Radiotherapy (START) trials are examined. Materials and methods: NTEs in the treated breast were recorded by (i) annual clinical assessments, (ii) photographs at 2 and 5 years, (iii) PROMs at 6 months, 1, 2 and 5 years after radiotherapy. Hazard ratios for the radiotherapy schedules were compared. Measures of agreement of assessments at 2 and 5 years tested concordance. Results: PROMs were available at 2 and/or 5 years for 1939 women, of whom 1870 had clinical and 1444 had photographic assessments. All methods were sensitive to the dose difference between schedules. Patients reported a higher prevalence for all NTE end points than clinicians or photographs (P < 0.001 for most NTEs). Concordance was generally poor; weighted kappa at 2 years ranged from 0.05 (telangiectasia) to 0.21 (shrinkage and oedema). The percentage agreement was lowest between PROMs and photographic assessments of change in breast appearance (38%). Conclusions: All three methods produced similar conclusions for the comparison of trial schedules, despite low concordance between the methods on an individual patient basis. Careful consideration should be given to the different contributions of the measures of NTE in future radiotherapy trials.
Introduction
Traditional outcome measures of normal tissue responses to radiotherapy rely heavily, often exclusively, on clinical assessments using graded scales to score a wide range of early and late adverse effects [1e4] . Scoring systems, including Late Effects in Normal Tissues Subjective, Objective, Management and Analytic (LENT-SOMA), Radiation Therapy Oncology Group (RTOG) and Common Terminology Criteria for Adverse Events (CTCAE), feature symptomatology requiring health professionals to elicit and score responses to direct questions. Photographic assessments of a change in breast appearance from a preradiotherapy baseline have become increasingly used in randomised trials of radiotherapy as they are usually scored by a small number of observers blind to patient identity, treatment allocation and year of follow-up, unlike the clinical assessments, which are scored by a large number of individuals in a multicentre study [5] . In parallel, the use of carefully developed and validated quality of life instruments in psychosocial research and phase III cancer clinical trials has expanded considerably [6e8], together with a growing interest in the use of patient-reported outcome measures (PROMS) in routine follow-up [9] . With an increasing use of PROMs in cancer clinical trials [10, 11] , it is worth asking how comparable and interpretable are the different methods of assessment, and whether PROMs could become the primary means of scoring late normal tissue effects (NTE) of breast radiotherapy in trials. Against this background, the large-scale UK Standardisation of Breast Radiotherapy (START) randomised trials [12e15] of hypofractionated radiotherapy after primary surgery for early breast cancer were used to conduct exploratory analyses comparing different methods of assessment of late NTE after adjuvant breast radiotherapy with the primary aim of assessing if PROMs might take priority over, or replace, clinical and/or photographic assessments as outcome measures.
Materials and Methods
The START-A and START-B trials recruited 4451 women between 1998 and 2002 from 35 UK radiotherapy centres (ISRCTN59368779, MREC(1)98/86). Centres could opt to participate in the PROMs and photographic assessment studies, and if they participated, they were expected to invite every eligible trial patient to join. Thirty-one (89%) centres opted to participate in the PROMs study and 29 (83%) in a photographic assessment study of the change in breast appearance. Women with operable invasive breast cancer (International Union Against Cancer pT1-3a pN0-1 M0) requiring radiotherapy after surgery (breastconserving surgery or mastectomy, with clear tumour margins 1 mm) were eligible for the trials if they were aged over 18 years, did not have an immediate surgical reconstruction and were available for follow-up. Trial A patients were randomised to either 50 Gy in 25 fractions (control) or 41.6 Gy in 13 fractions of 3.2 Gy or 39.0 Gy in 13 fractions of 3.0 Gy over 5 weeks. Trial B patients were randomised to either 50 Gy in 25 fractions over 5 weeks (control) or 40 Gy in 15 fractions of 2.7 Gy over 3 weeks. Full details of the recruitment, and radiotherapy planning, delivery and verification protocols have been previously reported, as has the PROMs study [12e14] .
Patients in the PROMs study completed baseline measures in clinic and were sent questionnaires to complete at home at 6 months, 1, 2 and 5 years after radiotherapy. Clinical assessments of NTE were collected at annual followup in all patients, and photographs were taken under standard conditions at a post-surgical pre-radiotherapy baseline and at 2 and 5 years after randomisation for patients who had breast-conserving surgery. The patient questionnaires included the (i) European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 core questionnaire and QLQ-BR23 breast-specific module [6, 16] , from which the assessment of breast swelling over the previous 4 weeks (not at all, a little, quite a bit, very much) was used in this study of concordance, (ii) Hospital Anxiety and Depression Scale [17] , (iii) 10-item Body Image Scale [18] and (iv) four protocol-specific questions asking patients to score 'change in breast appearance', 'breast hardness/ firmness', 'reduction in size of breast' and 'change in skin appearance' since radiotherapy; the first three questions applying only to patients with conserved breasts, and all items scored on a four-point scale (none, a little, quite a bit, very much).
The annual clinical assessments of breast shrinkage, breast induration, telangiectasia and breast oedema were scored using the contralateral breast as a comparator and four-point graded scales (none, a little, quite a bit, very much). Change in photographic breast appearance since radiotherapy was scored by a single team of three observers blind to patient identity, trial treatment allocation, year of follow-up and radiotherapy centre. The scoring method was validated in the START pilot trial [5] . Photographs at 2 and 5 years after radiotherapy were compared with a preradiotherapy (post-surgery) baseline and an overall score allocated for change in photographic breast appearance in the treated breast based on change in size, shrinkage and shape, on a three-point scale (no change, mild change, marked change). Post-mastectomy patients were included in the PROMs and clinical assessments but not in the photographic assessments. Individual NTE were mapped between the different assessment methods in order to compare corresponding outcomes, as shown in Table 1 .
Statistical Methods
NTE assessments at all time points in the trials were included in the comparison of radiotherapy schedules (i.e. from 6 months to 5 years for the PROMs, from 1 to 5 years for the clinical assessments, and at 2 and 5 years for the photographs). Time to first NTE event [defined as 'quite a bit' or 'very much' for the PROMs and clinical assessments, and any change (mild or marked) in photographic breast appearance] was calculated from the date of randomisation, and survival analysis methods used to compare radiotherapy schedules. Hazard ratios for the relative effects of the radiotherapy schedules in START-A were calculated for each NTE end point using Cox proportional hazards regression and compared between the different assessment methods using forest plots. Estimates of the a/b ratio for NTEs, which describes the sensitivity of normal tissues to fraction size, were obtained separately for the PROMs, clinician and photographic end points in START-A. Estimates of relative effects of the fractionation schedules in START-B are not presented in this paper as they do not contribute to the measurement of fraction sensitivity, only having two randomised groups in Trial B. Hazard ratios for the fractionation schedules in START-B have been published separately for the different NTE assessments, and showed consistent results [13e15].
For the concordance analyses, data from START Trials A and B were combined, and only 2 and 5 year assessments included as these were the time points at which all three NTE assessment methods were used in the trials. For all PROMs and clinically assessed end points there were few patients in the highest grade category, so moderate and marked categories were combined, resulting in three-point scales corresponding to none, a little ('mild'), quite a bit/ very much ('moderate/marked'); this also enabled comparison with the photographic assessments, which were scored on a similar three-point scale. Corresponding NTE end points were matched between the PROMs, clinical and photographic assessments at each time point and compared on an individual patient basis using measures of concordance, including percentage agreement (with 95% confidence interval), weighted kappa statistic (with 95% confidence interval) and Bowker's test of symmetry [19] . Guidelines for interpreting the value of the weighted kappa statistic in terms of the strength of agreement are <0.20: poor; 0.21e0.40: fair; 0.41e0.6: moderate; 0.61e0.8: good; 0.81e1.00: very good [20] . Bowker's test assesses the symmetry of a square table, i.e. whether there are more observations on one side of the diagonal than the other. The concordance analyses were also carried out stratifying on baseline patient characteristics such as age and quality of life scores (including anxiety and depression from the Hospital Anxiety and Depression Scale and body image from the Body Image Scale), to investigate whether these had any effect on the degree of concordance between NTE assessment methods.
Results
Of the 2208 women recruited into the overall START Trials PROMs study, self-assessments of NTEs were available at 2 and/or 5 years for 1939 (88%) patients, of whom 1870 also had clinical assessments at the same time points (85% of all patients in the PROMs study). Patient characteristics at baseline for the 1870 patients in this analysis are shown in Table 2 , of whom 1574/1870 (84.2%) had breast-conserving surgery and 1444/1574 (91%) had photographic assessments at 2 and/or 5 years.
Treatment effects on late NTE assessed by PROMs and by annual clinical assessment in START-A are shown side-byside in Figure 1 . Two test schedules (41.6 Gy and 39 Gy in 13 fractions) were compared with the control (50 Gy in 25 fractions) in START-A. Comparing hazard ratios for corresponding end points, it can be seen that the treatment effects were of a similar size for PROMs and clinical assessments, with overlapping confidence intervals. Treatment effects on late NTE assessed by PROMs and by photographs for overall change in breast appearance were also similar ( Figure 2 ). a/b estimates (adjusted for prognostic factors) for overall change in breast appearance were 2.9 Gy (95% confidence interval 0.7e5.1 Gy) for PROMs and 2.6 Gy (95% confidence interval 1.3e3.9 Gy) for photographic assessments. a/b estimates for individual NTE end points from clinical assessments have been reported [14] (there was no clinical assessment of overall cosmesis in the START Trials).
The comparison of overall rates of NTEs reported by PROMs and clinical assessments from START Trials A and B combined showed that patients reported a higher prevalence of breast changes (Figure 3aed ). Concordance between the assessments of corresponding NTEs on an individual patient basis was generally poor ( Table 3 ). The lowest levels of percentage agreement between PROMs and clinicians were observed for breast induration/hardness (47% and 50% at 2 and 5 years, respectively) and breast shrinkage (53% and 47% at 2 and 5 years). The highest level of percentage agreement between PROMs and clinicians was for breast swelling/oedema (78% and 86% at 2 and 5 years), but the overall prevalence of oedema was very low (Figure 3c ). Weighted kappa statistics also highlighted the low agreement between methods, ranging from 0.05 for telangiectasia at 2 years (indicating poor agreement) to 0.21 for each of breast shrinkage and breast oedema at 2 years (indicating fair agreement). Results of Bowker's test of symmetry were highly statistically significant for all NTE end points, indicating a clear direction in the discordance of scoring between the different methods, with patients reporting more breast changes compared with clinical and photographic assessments (Table 3 ). There seemed to be no substantial differences in degree of concordance for individual NTE end points according to time since radiotherapy, i.e. between 2 and 5 years ( Table 3 ).
The comparison of PROMs and photographic assessments showed that patients reported a higher prevalence of overall change in breast appearance since radiotherapy and graded effects as more severe compared with the photographic assessments (Figure 3e ). In testing concordance, agreement on an individual patient basis was low at 2 and 5 years (38% for each), with low weighted kappa values (0.09) and highly statistically significant discordance (P < 0.001 for Bowker's test of symmetry); Table 3 . Concordance of PROMs with clinical and photographic assessments of NTE seem to be unaffected by patient factors, including age, breast size, surgical deficit, baseline Hospital Anxiety and Depression Scale anxiety and depression and body image scores (see table in web appendix).
Discussion
Concordance between PROMs and NTE assessments as scored by clinicians and from photographs on an individual patient basis was poor. The percentage agreement between PROMs and clinical assessments of specific NTEs was around 50%, indicating that in only half the patients the NTE was graded in the same category of severity corresponding to none, mild, moderate/marked. Agreement was even lower between PROMs and photographs, where less than 40% graded NTEs the same. In our study, patients scored NTEs more frequently and more severely than results from clinicians or photographs. Concordance did not seem to be affected by patient characteristics, including psychological measures (anxiety and depression), body image and factors associated with risk of NTEs (age, breast size and surgical deficit). It may not be surprising that concordance between the assessment methods on an individual patient basis was poor; this has been consistently reported in other studies [21e24]. These differences in ratings reflect the different paradigms in which symptoms are perceived and rated; these include variance in context, values, expectations and methodological influences, as well as the different sociocultural backgrounds of subjects and doctors [25] . Published comparisons of clinician and patient selfassessments show considerable variability between ratings, especially for more subjective symptoms and often report, as in our study, a relative underestimate by clinicians compared with patients (e.g. [23,24,26e30] ). However, the concordance analysis of NTE assessments in the Cambridge intensity-modulated breast radiotherapy trial found the opposite, with clinicians and photographic assessments reporting more NTEs compared with patients, possibly because the study was carried out in a single centre, with clinical ratings carried out by one person [31] . Others have shown a more favourable rating of overall cosmesis after conservative treatment for breast cancer by patients compared with clinicians [32, 33] , although these findings are not necessarily specific to late effects of radiotherapy. Kirchheiner et al. [34] argued that some variation is 'quite acceptable and comprehensible', given the methodological differences between morbidity scoring by clinicians and patient-reported symptoms. Clinical and patient symptom ratings are typically not designed to be interchangeable, given that they often have different values and purposes, with patient assessments inherently encompassing impact on quality of life. However, our study showed that despite the discordance between assessments on an individual basis, the three methods (PROMs, clinical and photographs) generated similar estimates of relative treatment effects on NTE within the trials [12, 14, 15] . The discriminatory power of different assessments was equally good, in that PROMs generated the same estimates of a/b value for NTE in START-A (around 3 Gy) as photographs and clinical assessments (data for a/b values of clinical assessments of NTEs previously published [14] ). From the trial outcome perspective, this consistency of treatment effects adds considerable weight to the overall interpretation and conclusions of the trial. However, the PROMs reported here were selected from a large number of multidimensional items assessed as part of the START quality of life sub-study, most of which would not be expected to discriminate so clearly between the schedules in the START trials, but are of value in understanding the experience of treatment effects over time. The PROMs items included in this analysis of concordance were those directly relevant to the hypothesis under test in the clinical trial and therefore probably sensitive to randomised differences in radiotherapy dose intensity. The PROMs needed to have a recognisable relationship with the pathophysiology (atrophy, fibrosis) of NTE, broadly corresponding to clinical scoring of change in size (atrophy), shape and texture (oedema, fibrosis) of the breast and change in photographic breast appearance (atrophy, distortion/fibrosis). This is in contrast with other clinically relevant domains, such as physical and social functioning, that explore the effect on different aspects of quality of life [6, 16] .
Clinicians are taught in training that symptomatology is the key to diagnosis, which they can only judge by listening to their patients and framing relevant questions. Clinicians act as surrogates for their patients in this context, so that if the relevant questions are known in advance (as they are in a clinical trial), there seems to be a good reason to prioritise the PROMs over the physical clinical assessments. Where physical signs are concerned, including breast size, shape and texture, this study suggests that patients are as sensitive as their doctors in scoring these changes too, provided the questions are framed appropriately. In this respect, it is possible to criticise our PROMs question, which asked patients to score changes since radiotherapy to the affected breast compared with the clinical assessment that compared the treated with the untreated breast at the time of the annual examination. Despite a variety of factors expected to influence how a woman responds to this question, the sensitivity to randomised dose indicates that the radiotherapy 'signal' was not lost. Doctors also develop their own frames of reference when assessing NTE, and the hundreds of clinical observers involved in scoring NTE in thousands of patients over a 10 year period, as in the START trials, necessarily contribute a lot of 'noise' in a scoring system. However, a disadvantage of reliance on PROMs in clinical trials is that they are traditionally labour-intensive to administer and generate large volumes of data, making heavy demands on trial management and statistical resources. Since modern data capture systems are increasingly able to collect outcome data directly from the patient (e.g. via an App), dispensing with clinical follow-up may appeal to patients as well as health services operating under increasing pressures [35] . However, radiation effects are not viewed in isolation by patients and attention also needs to be paid to their concerns in the context of multimodal treatments and adverse effects over time. Up to a third of patients report moderate or marked symptoms of the breast, arm and shoulder at 5 years, which may warrant engagement and advice from their clinical teams [13] . Thus, more preparation and after care is needed for the success of patient self-management post-treatment and to improve quality of life [36] . Furthermore, the acceptability of electronic symptom reporting warrants evaluation in an aging population.
Despite adding to the administrative burden of clinical trials, the photographic assessments of NTEs provide valuable information, not least because they are scored generally by the same small team of observers who are blind to patient identity, randomised treatment allocation, year of follow-up and participating hospital. As it is generally not possible to blind treatment allocation in radiotherapy trials, the photographic assessments provide the only unbiased comparison of NTEs between randomised groups. In addition, as photographs provide a permanent record of breast effects at a fixed point in time, the assessments can be validated by repeat scoring from different teams of observers [5] , thus making the scoring more standardised than PROMs or clinical assessments from physical examination. Photographs can also be filed and stored for use in future translational research investigating adverse effects of radiotherapy. There are some disadvantages to the use of photographic assessments in clinical trials, including financial and staff resources required, and they can be disliked by patients, but these are outweighed by the benefits of retaining an unbiased comparison of NTEs within radiotherapy trials.
There is growing interest in investigating inherited risk factors for radiotherapy NTE, for which robust measures of NTE are needed that have a close relationship to the underlying pathophysiology [37] . In this respect, the lack of concordance reported in this study is intriguing and potentially worrying. The prevalence and severity of NTEs reported by patients, clinicians and from photographs during follow-up were widely discordant in most cases. In trying to identify subgroups of patients with levels of NTE that are much more, or much less, severe than expected on the basis of known factors (breast size, radiotherapy dose etc.), it is not possible to judge whether the clinical and photographic assessments of NTE severity are more or less valid than the PROMs, hence making identification of potential cases (and controls) for translational studies very difficult. Perhaps much depends on how the NTE assessment questions to patients and clinicians are posed, something that this study does not address.
In conclusion, the PROMs, clinical and photographic assessments of late NTE in the START trials generated consistent estimates of relative treatment effects between randomised groups, adding weight to the trials' overall findings. Discordance in the prevalence rates of NTE reported by the patients, clinicians and photographs could be expected for a number of well-established reasons, but this does not undermine an argument for prioritising PROMs and photographic assessments of NTEs in breast radiotherapy trials.
